测试将 Nivolumab 添加到具有 BRAF 突变的转移性或不可切除的结直肠癌患者的标准治疗中
Encorafenib 和 Cetuximab 联合或不联合 Nivolumab (NSC #748726) 的随机 II 期试验用于既往接受过治疗、微卫星稳定、BRAFV600E 转移性和/或不可切除的结直肠癌患者
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients with microsatellite stable (MSS), BRAF^V600E metastatic and/or unresectable colorectal cancer (CRC) randomized to treatment with nivolumab + encorafenib + cetuximab compared to encorafenib + cetuximab.
SECONDARY OBJECTIVES:
I. To compare overall response rate (ORR), including confirmed and unconfirmed, complete and partial response, according to RECIST 1.1 criteria between the two arms.
II. To compare overall survival (OS) between the two arms. III. To compare duration of response between the two arms. IV. To compare safety and tolerability between the two arms. V. To assess immune-related PFS using modified response criteria adapted for immunotherapy (irRC-PFS) in patients treated with nivolumab + encorafenib + cetuximab.
BANKING OBJECTIVE:
I. To bank tissue and blood specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive encorafenib orally (PO) once daily (QD) on days 1-28, cetuximab intravenously (IV) on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed until death or 3 years after registration, whichever occurs first.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Bayamón、波多黎各、00961
- Puerto Rico Hematology Oncology Group
-
San Juan、波多黎各、00927
- Centro Comprensivo de Cancer de UPR
-
San Juan、波多黎各、00936
- San Juan City Hospital
-
San Juan、波多黎各、00927
- PROncology
-
-
-
-
Arizona
-
Goodyear、Arizona、美国、85338
- CTCA at Western Regional Medical Center
-
-
California
-
Carmichael、California、美国、95608
- Mercy San Juan Medical Center
-
Carmichael、California、美国、95608
- Mercy Cancer Center - Carmichael
-
Dublin、California、美国、94568
- Kaiser Permanente Dublin
-
Elk Grove、California、美国、95758
- Mercy Cancer Center - Elk Grove
-
Fremont、California、美国、94538
- Kaiser Permanente-Fremont
-
Fresno、California、美国、93720
- Kaiser Permanente-Fresno
-
Irvine、California、美国、92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Modesto、California、美国、95356
- Kaiser Permanente-Modesto
-
Oakland、California、美国、94611
- Kaiser Permanente-Oakland
-
Orange、California、美国、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Rocklin、California、美国、95765
- Mercy Cancer Center - Rocklin
-
Roseville、California、美国、95661
- Kaiser Permanente-Roseville
-
Sacramento、California、美国、95814
- Kaiser Permanente Downtown Commons
-
Sacramento、California、美国、95823
- Kaiser Permanente-South Sacramento
-
Sacramento、California、美国、95816
- Mercy Cancer Center - Sacramento
-
San Francisco、California、美国、94115
- Kaiser Permanente-San Francisco
-
San Jose、California、美国、95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro、California、美国、94577
- Kaiser Permanente San Leandro
-
Santa Clara、California、美国、95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa、California、美国、95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco、California、美国、94080
- Kaiser Permanente-South San Francisco
-
Vallejo、California、美国、94589
- Kaiser Permanente-Vallejo
-
Walnut Creek、California、美国、94596
- Kaiser Permanente-Walnut Creek
-
Woodland、California、美国、95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora、Colorado、美国、80045
- UCHealth University of Colorado Hospital
-
Colorado Springs、Colorado、美国、80909
- UCHealth Memorial Hospital Central
-
Colorado Springs、Colorado、美国、80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs、Colorado、美国、80920
- Memorial Hospital North
-
Fort Collins、Colorado、美国、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、美国、80528
- Cancer Care and Hematology-Fort Collins
-
Greeley、Colorado、美国、80631
- UCHealth Greeley Hospital
-
Highlands Ranch、Colorado、美国、80129
- UCHealth Highlands Ranch Hospital
-
Loveland、Colorado、美国、80538
- Medical Center of the Rockies
-
-
Georgia
-
Newnan、Georgia、美国、30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、美国、96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise、Idaho、美国、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、美国、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、美国、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、美国、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、美国、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、美国、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、美国、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、美国、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、美国、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、美国、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、美国、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora、Illinois、美国、60504
- Rush-Copley Medical Center
-
Barrington、Illinois、美国、60010
- Advocate Good Shepherd Hospital
-
Bloomington、Illinois、美国、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、美国、61520
- Illinois CancerCare-Canton
-
Carthage、Illinois、美国、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、美国、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、美国、60612
- University of Illinois
-
Chicago、Illinois、美国、60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake、Illinois、美国、60014
- AMG Crystal Lake - Oncology
-
Danville、Illinois、美国、61832
- Carle at The Riverfront
-
Decatur、Illinois、美国、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、美国、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、美国、61021
- Illinois CancerCare-Dixon
-
Downers Grove、Illinois、美国、60515
- Advocate Good Samaritan Hospital
-
Effingham、Illinois、美国、62401
- Crossroads Cancer Center
-
Effingham、Illinois、美国、62401
- Carle Physician Group-Effingham
-
Elgin、Illinois、美国、60123
- Advocate Sherman Hospital
-
Eureka、Illinois、美国、61530
- Illinois CancerCare-Eureka
-
Galesburg、Illinois、美国、61401
- Illinois CancerCare-Galesburg
-
Hazel Crest、Illinois、美国、60429
- Advocate South Suburban Hospital
-
Kewanee、Illinois、美国、61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville、Illinois、美国、60048
- Condell Memorial Hospital
-
Libertyville、Illinois、美国、60048
- AMG Libertyville - Oncology
-
Macomb、Illinois、美国、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、美国、61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon、Illinois、美国、62269
- Cancer Care Center of O'Fallon
-
Oak Lawn、Illinois、美国、60453-2699
- Advocate Christ Medical Center
-
Ottawa、Illinois、美国、61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge、Illinois、美国、60068
- Advocate Lutheran General Hospital
-
Pekin、Illinois、美国、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、美国、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、美国、61354
- Illinois CancerCare-Peru
-
Princeton、Illinois、美国、61356
- Illinois CancerCare-Princeton
-
Springfield、Illinois、美国、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、美国、62702
- Springfield Clinic
-
Springfield、Illinois、美国、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、美国、61801
- Carle Cancer Center
-
Washington、Illinois、美国、61571
- Illinois CancerCare - Washington
-
Yorkville、Illinois、美国、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Crown Point、Indiana、美国、46307
- Northwest Cancer Center - Crown Point
-
Dyer、Indiana、美国、46311
- Northwest Oncology LLC
-
Hobart、Indiana、美国、46342
- Northwest Cancer Center - Hobart
-
Hobart、Indiana、美国、46342
- Saint Mary Medical Center
-
Indianapolis、Indiana、美国、46237
- Franciscan Health Indianapolis
-
Indianapolis、Indiana、美国、46312
- Saint Catherine Hospital
-
Lafayette、Indiana、美国、47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City、Indiana、美国、46360
- Woodland Cancer Care Center
-
Mooresville、Indiana、美国、46158
- Franciscan Health Mooresville
-
Munster、Indiana、美国、46321
- The Community Hospital
-
Munster、Indiana、美国、46321
- Women's Diagnostic Center - Munster
-
Valparaiso、Indiana、美国、46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Ames、Iowa、美国、50010
- Mary Greeley Medical Center
-
Ames、Iowa、美国、50010
- McFarland Clinic - Ames
-
Boone、Iowa、美国、50036
- McFarland Clinic - Boone
-
Des Moines、Iowa、美国、50314
- Mercy Medical Center - Des Moines
-
Fort Dodge、Iowa、美国、50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson、Iowa、美国、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、美国、50158
- McFarland Clinic - Marshalltown
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge、Louisiana、美国、70808
- Our Lady of the Lake Physician Group
-
Covington、Louisiana、美国、70433
- Ochsner Hematology Oncology North Shore - Covington (West Region)
-
New Orleans、Louisiana、美国、70121
- Ochsner Medical Center Jefferson
-
-
Michigan
-
Ann Arbor、Michigan、美国、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek、Michigan、美国、49017
- Bronson Battle Creek
-
Brighton、Michigan、美国、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton、Michigan、美国、48114
- Trinity Health Medical Center - Brighton
-
Canton、Michigan、美国、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton、Michigan、美国、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、美国、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea、Michigan、美国、48118
- Chelsea Hospital
-
Detroit、Michigan、美国、48202
- Henry Ford Hospital
-
Detroit、Michigan、美国、48236
- Henry Ford Health Saint John Hospital
-
East China Township、Michigan、美国、48054
- Henry Ford River District Hospital
-
Flint、Michigan、美国、48503
- Hurley Medical Center
-
Flint、Michigan、美国、48503
- Genesee Hematology Oncology PC
-
Flint、Michigan、美国、48503
- Genesys Hurley Cancer Institute
-
Flint、Michigan、美国、48503
- Cancer Hematology Centers - Flint
-
Grand Rapids、Michigan、美国、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、美国、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grosse Pointe Woods、Michigan、美国、48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods、Michigan、美国、48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo、Michigan、美国、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、美国、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、美国、49009
- Beacon Kalamazoo Cancer Center
-
Lansing、Michigan、美国、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、美国、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb、Michigan、美国、48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Muskegon、Michigan、美国、49444
- Trinity Health Muskegon Hospital
-
Niles、Michigan、美国、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、美国、49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi、Michigan、美国、48377
- Henry Ford Medical Center-Columbus
-
Novi、Michigan、美国、48374
- Henry Ford Health Providence Novi Hospital
-
Reed City、Michigan、美国、49677
- Corewell Health Reed City Hospital
-
Saginaw、Michigan、美国、48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、美国、48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph、Michigan、美国、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Southfield、Michigan、美国、48075
- Henry Ford Health Providence Southfield Hospital
-
Sterling Heights、Michigan、美国、48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City、Michigan、美国、48764
- MyMichigan Medical Center Tawas
-
Traverse City、Michigan、美国、49684
- Munson Medical Center
-
Warren、Michigan、美国、48093
- Macomb Hematology Oncology PC
-
Warren、Michigan、美国、48093
- Henry Ford Health Warren Hospital
-
Warren、Michigan、美国、48093
- Henry Ford Warren Hospital - GLCMS
-
West Bloomfield、Michigan、美国、48322
- Henry Ford West Bloomfield Hospital
-
West Branch、Michigan、美国、48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming、Michigan、美国、49519
- University of Michigan Health - West
-
Ypsilanti、Michigan、美国、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti、Michigan、美国、48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Coon Rapids、Minnesota、美国、55433
- Mercy Hospital
-
Deer River、Minnesota、美国、56636
- Essentia Health - Deer River Clinic
-
Duluth、Minnesota、美国、55805
- Essentia Health Cancer Center
-
Edina、Minnesota、美国、55435
- Fairview Southdale Hospital
-
Hibbing、Minnesota、美国、55746
- Essentia Health Hibbing Clinic
-
Minneapolis、Minnesota、美国、55407
- Abbott-Northwestern Hospital
-
Robbinsdale、Minnesota、美国、55422
- North Memorial Medical Health Center
-
Saint Louis Park、Minnesota、美国、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、美国、55101
- Regions Hospital
-
Saint Paul、Minnesota、美国、55102
- United Hospital
-
Sandstone、Minnesota、美国、55072
- Essentia Health Sandstone
-
Virginia、Minnesota、美国、55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau、Missouri、美国、63703
- Saint Francis Medical Center
-
-
Montana
-
Anaconda、Montana、美国、59711
- Community Hospital of Anaconda
-
Billings、Montana、美国、59101
- Billings Clinic Cancer Center
-
Bozeman、Montana、美国、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、美国、59405
- Benefis Sletten Cancer Institute
-
Kalispell、Montana、美国、59901
- Logan Health Medical Center
-
Missoula、Montana、美国、59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Flemington、New Jersey、美国、08822
- Hunterdon Medical Center
-
-
New York
-
Buffalo、New York、美国、14263
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton、North Carolina、美国、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、美国、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville、North Carolina、美国、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Pinehurst、North Carolina、美国、28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
-
Ohio
-
Belpre、Ohio、美国、45714
- Strecker Cancer Center-Belpre
-
Centerville、Ohio、美国、45459
- Miami Valley Hospital South
-
Chillicothe、Ohio、美国、45601
- Adena Regional Medical Center
-
Columbus、Ohio、美国、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、美国、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、美国、43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus、Ohio、美国、43228
- Doctors Hospital
-
Columbus、Ohio、美国、43213
- Mount Carmel East Hospital
-
Columbus、Ohio、美国、43215
- Grant Medical Center
-
Dayton、Ohio、美国、45409
- Miami Valley Hospital
-
Dayton、Ohio、美国、45415
- Miami Valley Hospital North
-
Dayton、Ohio、美国、45415
- Dayton Physician LLC - Englewood
-
Dayton、Ohio、美国、45409
- Premier Blood and Cancer Center
-
Delaware、Ohio、美国、43015
- Delaware Health Center-Grady Cancer Center
-
Delaware、Ohio、美国、43015
- Grady Memorial Hospital
-
Dublin、Ohio、美国、43016
- Columbus Oncology and Hematology Associates
-
Franklin、Ohio、美国、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin、Ohio、美国、45005
- Dayton Physicians LLC-Atrium
-
Greenville、Ohio、美国、45331
- Miami Valley Cancer Care and Infusion
-
Grove City、Ohio、美国、43123
- Mount Carmel Grove City Hospital
-
Kettering、Ohio、美国、45429
- Kettering Medical Center
-
Lancaster、Ohio、美国、43130
- Fairfield Medical Center
-
Mansfield、Ohio、美国、44903
- OhioHealth Mansfield Hospital
-
Marion、Ohio、美国、43302
- OhioHealth Marion General Hospital
-
Marysville、Ohio、美国、43040
- Memorial Hospital
-
Mount Vernon、Ohio、美国、43050
- Knox Community Hospital
-
Newark、Ohio、美国、43055
- Licking Memorial Hospital
-
Portsmouth、Ohio、美国、45662
- Southern Ohio Medical Center
-
Springfield、Ohio、美国、45504
- Springfield Regional Cancer Center
-
Springfield、Ohio、美国、45504
- Springfield Regional Medical Center
-
Toledo、Ohio、美国、43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy、Ohio、美国、45373
- Upper Valley Medical Center
-
Westerville、Ohio、美国、43081
- Saint Ann's Hospital
-
Zanesville、Ohio、美国、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton、Oklahoma、美国、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、美国、73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Clackamas、Oregon、美国、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、美国、97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg、Oregon、美国、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、美国、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City、Oregon、美国、97045
- Providence Willamette Falls Medical Center
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
Portland、Oregon、美国、97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、美国、18017
- Lehigh Valley Hospital - Muhlenberg
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania/Abramson Cancer Center
-
West Reading、Pennsylvania、美国、19611
- Reading Hospital
-
-
Rhode Island
-
Providence、Rhode Island、美国、02903
- Rhode Island Hospital
-
-
South Carolina
-
Boiling Springs、South Carolina、美国、29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
Easley、South Carolina、美国、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、美国、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、美国、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、美国、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、美国、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、美国、29650
- Prisma Health Cancer Institute - Greer
-
Seneca、South Carolina、美国、29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo、Texas、美国、79106
- The Don and Sybil Harrington Cancer Center
-
Dallas、Texas、美国、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、美国、75237
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth、Texas、美国、76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Houston、Texas、美国、77030
- UT MD Anderson Cancer Center
-
Richardson、Texas、美国、75080
- UT Southwestern Clinical Center at Richardson/Plano
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury、Vermont、美国、05819
- Dartmouth Cancer Center - North
-
-
Washington
-
Edmonds、Washington、美国、98026
- Swedish Cancer Institute-Edmonds
-
Issaquah、Washington、美国、98029
- Swedish Cancer Institute-Issaquah
-
Seattle、Washington、美国、98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Bridgeport、West Virginia、美国、26330
- United Hospital Center
-
Morgantown、West Virginia、美国、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton、Wisconsin、美国、54911
- ThedaCare Regional Cancer Center
-
Ashland、Wisconsin、美国、54806
- Duluth Clinic Ashland
-
Burlington、Wisconsin、美国、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy、Wisconsin、美国、53110
- Aurora Saint Luke's South Shore
-
Eau Claire、Wisconsin、美国、54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown、Wisconsin、美国、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、美国、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、美国、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、美国、53142
- Aurora Cancer Care-Kenosha South
-
Marinette、Wisconsin、美国、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、美国、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、美国、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、美国、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、美国、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、美国、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、美国、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、美国、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、美国、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh、Wisconsin、美国、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、美国、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、美国、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、美国、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、美国、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、美国、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、美国、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha、Wisconsin、美国、53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa、Wisconsin、美国、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、美国、53227
- Aurora West Allis Medical Center
-
Weston、Wisconsin、美国、54476
- Marshfield Medical Center - Weston
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum. The date of diagnosis will be determined according to the pathologic date of diagnosis
-
Participants must have measurable disease according to RECIST1.1 criteria. Computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have documented unresectable and/or metastatic disease on CT or MRI imaging. All disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have BRAF^V600E mutated colorectal cancer as tested in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory
-
Participants must have proficient mismatch repair (pMMR) or microsatellite stable (MSS) status as tested in a CLIA-certified laboratory and documented by the treating clinician. Proficient mismatch repair status can be determined by intact expression by immunohistochemistry of all 4 mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). Microsatellite instability can be determined by polymerase chain reaction (PCR)
-
Participants with brain metastases must have completed surgery or radiation therapy >= 28 days prior to registration. These participants must have a CT or MRI of the brain showing no new or enlarging lesions within 42 days prior to registration. These participants must also be neurologically asymptomatic and without corticosteroid treatment for at least 7 days prior to registration. Metastatic brain parenchymal disease must have been treated and participant must be off steroids for 7 days prior to registration. The presence of leptomeningeal disease (LMD) is not considered stable disease, and participants with LMD are not eligible for this study
-
Participants with known evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration
-
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration
-
Participants must have had one or two prior regimens of systemic chemotherapy for metastatic or locally advanced, unresectable disease. (A maintenance regimen of 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted as a separate line of treatment. The re-introduction of an initially successful induction regimen will not be counted as one additional line of treatment). Prior treatment for metastatic disease is not required for patients who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy
-
Participants must be of age >= 18 years at the time of informed consent
-
Participants must have a Zubrod performance status of 0 or 1
-
Participants must have a complete medical history and physical exam within 28 days prior to registration
-
Absolute neutrophil count >= 1.0 x 10^3/uL (within 28 days prior to registration)
-
Hemoglobin >= 9 g/dL (within 28 days prior to registration)
-
Platelets >= 75 x 10^3/uL (within 28 days prior to registration)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to registration)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to registration)
-
If liver metastases are present, then it is acceptable for AST level =< 5.0 x ULN, and/or an ALT level =< 5.0 x ULN (within 28 days prior to registration)
-
Participants must have serum creatinine =< the IULN OR measured OR calculated creatinine clearance >= 50 mL/min using the Cockroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration
-
Participants must be able to swallow and retain pills
-
Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better
-
Participants with a known significant risk of corrected QT interval (QTc) prolongation must have an electrocardiogram (ECG) performed within 28 days prior to prior to registration
- Note: Per package insert for encorafenib, participants already at risk for development of QTc prolongation include those who "already have or who are at significant risk of developing QTc prolongation, including participants with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation."
-
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- Note: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Exclusion Criteria:
-
Participants must not have a known positive serology for human immunodeficiency virus (HIV). Encorafenib is contraindicated with concomitant use of non-nucleoside analog reverse transcriptase inhibitors like efavirenz and etravirine. In addition, it is recommended in the investigator brochure of encorafenib to avoid using encorafenib with protease inhibitors. Therefore, because all participants on this study would receive encorafenib for either randomized arm of treatment, participants with HIV who receive these components of highly active antiretroviral therapy (HAART) would be at high risk for complications of drug-drug interaction
-
Participants must not have had prior treatment with a BRAF inhibitor (including, but not limited to, encorafenib, dabrafenib, or vemurafenib), MEK inhibitor (including, but not limited to, trametinib, selumetinib, or binimetinib), or ERK inhibitor (of note, regorafenib is not considered a BRAF inhibitor for the context of eligibility criteria)
-
Participants must not have had prior treatment with anti-EGFR therapies
-
Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted, as long as there has been a washout period for corticosteroids of >= 7 days prior to registration
-
Participants must not have received a live vaccine within 30 days prior to study registration. Seasonal flu and COVID vaccines that do not contain a live virus are permitted
-
Participants must not be receiving any other investigational agents
-
Participants must not have impaired gastrointestinal function or disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
-
Participants must not have a history of inflammatory bowel disease, (including ulcerative colitis and Crohn's disease), symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); central nervous system (CNS) or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and myasthenia gravis, multiple sclerosis).
- Note: Participants with Graves' disease will be allowed
-
Participants must not have a history of pneumonitis that has required oral or intravenous (IV) steroids within the last 12 months
-
Participants must not have a history of a grade 3 or 4 allergic reaction attributed to humanized or human monoclonal antibody therapy
-
Participants must not have a history of a prior allogeneic tissue or solid organ transplant
-
Participants must not have a history of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) within 6 months prior to study registration
-
Participants must not have uncontrolled blood pressure and hypertension within 28 days prior to registration.
- Uncontrolled blood pressure and hypertension is defined as systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg within 28 days prior to registration. Participants are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study). All blood pressure measurements within the 28 days prior to registration must be SBP < 160 and DBP =< 100. An exception can be made by a healthcare provider for a participant with a single blood pressure elevation who upon rechecking has a normal blood pressure
-
Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen or requires concurrent therapy
-
Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion and vasectomy with testing showing no sperm in the semen
-
Participants must not be planning treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any type
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (encorafenib, cetuximab, nivolumab)
Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
其他名称:
Given IV
其他名称:
Given PO
其他名称:
|
|
有源比较器:Arm II (encorafenib, cetuximab)
Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
其他名称:
Given PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS)
大体时间:From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
Conducted in all eligible participants according to the intent-to-treat principle using the stratified log rank test when a total of 66 PFS events have been observed. Estimated using the Kaplan-Meier method and compared using the stratified log rank test. |
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall response rate (ORR)
大体时间:Up to 3 years
|
Evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (confirmed and unconfirmed, complete and partial response) and compared across treatment arms via Fisher's exact test. |
Up to 3 years
|
|
Overall survival (OS)
大体时间:From date of registration to date of death due to any cause, assessed up to 3 years
|
Estimated using the Kaplan-Meier method and compared using the stratified log rank test. The distribution of OS will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
From date of registration to date of death due to any cause, assessed up to 3 years
|
|
Duration of response (DoR)
大体时间:From date of first documentation of confirmed response (complete response or partial response) to date of first documentation of progression or symptomatic deterioration or death due to any cause among participants who achieve a response, up to 3 years
|
Estimated using the Kaplan-Meier method and compared using the stratified log rank test. The distribution of DoR will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
From date of first documentation of confirmed response (complete response or partial response) to date of first documentation of progression or symptomatic deterioration or death due to any cause among participants who achieve a response, up to 3 years
|
|
Immune related progression-free survival (irRC-PFS) in Arm I
大体时间:From date of registration to date of initial documentation of irRC-progression that has subsequently been confirmed or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
The distribution of irRC-PFS in Arm 1 (nivolumab + encorafenib + cetuximab) will be estimated using the method of Kaplan-Meier. |
From date of registration to date of initial documentation of irRC-progression that has subsequently been confirmed or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
|
Incidence of adverse events
大体时间:Up to 3 years
|
At least 25 eligible participants in each arm are sufficient to estimate the probability of a particular toxicity within ±20% (95% confidence interval), and any toxicity occurring with at least 10% probability is likely (93% chance) to be seen at least once. At least 50 eligible participants are sufficient to estimate the probability of a particular toxicity within ±14% (95% confidence interval), and any toxicity occurring with at least 5% probability is likely (92% chance) to be seen at least once. |
Up to 3 years
|
合作者和调查者
调查人员
- 首席研究员:Van K Morris、SWOG Cancer Research Network
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2022-02494
- U10CA180888 (美国 NIH 拨款/合同)
- NCI-2022-02494 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- S2107 (其他标识符:CTEP)
- S2107 (其他标识符:SWOG)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.